WO2012165888A9 - 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만, 항당뇨 및 근육량 증대및 운동력 향상용 조성물 - Google Patents
파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만, 항당뇨 및 근육량 증대및 운동력 향상용 조성물 Download PDFInfo
- Publication number
- WO2012165888A9 WO2012165888A9 PCT/KR2012/004325 KR2012004325W WO2012165888A9 WO 2012165888 A9 WO2012165888 A9 WO 2012165888A9 KR 2012004325 W KR2012004325 W KR 2012004325W WO 2012165888 A9 WO2012165888 A9 WO 2012165888A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- composition
- fruit
- retrofractum
- pfeiffer
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 210000003205 muscle Anatomy 0.000 title claims abstract description 35
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 21
- 235000019510 Long pepper Nutrition 0.000 title claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 title claims description 25
- 240000003455 Piper longum Species 0.000 title claims description 13
- 239000004480 active ingredient Substances 0.000 title claims description 9
- 230000001965 increasing effect Effects 0.000 title abstract description 14
- 208000008589 Obesity Diseases 0.000 title description 12
- 235000020824 obesity Nutrition 0.000 title description 12
- 230000000694 effects Effects 0.000 claims abstract description 46
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 18
- 230000003579 anti-obesity Effects 0.000 claims abstract description 18
- 102000004877 Insulin Human genes 0.000 claims abstract description 17
- 108090001061 Insulin Proteins 0.000 claims abstract description 17
- 229940125396 insulin Drugs 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 14
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 6
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 230000003178 anti-diabetic effect Effects 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 17
- 239000003472 antidiabetic agent Substances 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 6
- 230000037147 athletic performance Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 230000037396 body weight Effects 0.000 abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 239000008103 glucose Substances 0.000 abstract description 6
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 240000002286 Piper retrofractum Species 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000035924 thermogenesis Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 241000722363 Piper Species 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 6
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 6
- 238000010162 Tukey test Methods 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 238000010149 post-hoc-test Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000020169 heat generation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 241000758706 Piperaceae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VOZJBFJHMHRLDN-ZUVMSYQZSA-N methyl (2e,4e)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate Chemical compound COC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 VOZJBFJHMHRLDN-ZUVMSYQZSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 2
- 229940075559 piperine Drugs 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FPMPOFBEYSSYDQ-AUVZEZIHSA-N Guineensine Chemical compound CC(C)CNC(=O)\C=C\C=C\CCCCCC\C=C\C1=CC=C2OCOC2=C1 FPMPOFBEYSSYDQ-AUVZEZIHSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- VOZJBFJHMHRLDN-UHFFFAOYSA-N Methylpiperat Natural products COC(=O)C=CC=CC1=CC=C2OCOC2=C1 VOZJBFJHMHRLDN-UHFFFAOYSA-N 0.000 description 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 1
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 1
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 1
- 101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- RPOYGOULCHMVBB-ADDDGJNWSA-N Pipercide Chemical compound CC(C)CNC(=O)\C=C\C=C\CCCC\C=C\C1=CC=C2OCOC2=C1 RPOYGOULCHMVBB-ADDDGJNWSA-N 0.000 description 1
- DYIPBGULDOZWPD-UPZYHHBKSA-N Pipercide Natural products O=C(N[C@H](CC)C)/C=C/C=C/CCCC/C=C/c1cc2OCOc2cc1 DYIPBGULDOZWPD-UPZYHHBKSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- AHEYHYFMDFGWEG-FMQCLRLRSA-N Retrofractamide A Natural products O=C(N[C@@H](CC)C)/C=C/C=C/CC/C=C/c1cc2OCOc2cc1 AHEYHYFMDFGWEG-FMQCLRLRSA-N 0.000 description 1
- BPSWISYORIWKCT-FCGWLDPVSA-N Retrofractamide A Chemical compound CC(C)CNC(=O)\C=C\C=C\CC\C=C\C1=CC=C2OCOC2=C1 BPSWISYORIWKCT-FCGWLDPVSA-N 0.000 description 1
- RPOYGOULCHMVBB-FAZSMNIISA-N Retrofractamide B Natural products CC(C)CNC(=O)C=C/C=C/CCCCC=C/c1ccc2OCOc2c1 RPOYGOULCHMVBB-FAZSMNIISA-N 0.000 description 1
- PAXQNYHJDFKFEU-FIFLTTCUSA-N Retrofractamide C Chemical compound CC(C)CNC(=O)\C=C\CCCC\C=C\C1=CC=C2OCOC2=C1 PAXQNYHJDFKFEU-FIFLTTCUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- YMEOKCQRDKKTBN-UNRFKFNXSA-N guineensine Natural products O=C(N[C@@H](CC)C)/C=C/C=C/CCCCCC/C=C/c1cc2OCOc2cc1 YMEOKCQRDKKTBN-UNRFKFNXSA-N 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- PAXQNYHJDFKFEU-UHFFFAOYSA-N retrofractamide-C Natural products CC(C)CNC(=O)C=CCCCCC=CC1=CC=C2OCOC2=C1 PAXQNYHJDFKFEU-UHFFFAOYSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- -1 starch Polymers 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Definitions
- the present invention relates to a novel use of a composition containing a composition for the prevention and treatment of obesity and diabetes, as well as muscle mass gain and athletic performance, and more particularly, extract of Piper retrofractum Vahl.
- Functional food suitable for improving exercise performance including endurance by increasing fever, reducing weight and body fat, increasing anti-diabetic function to reduce blood sugar and insulin levels of human body, increasing supply of energy source of muscle of human body
- compositions or pharmaceutical compositions are provided.
- UCP uncoupling protein
- UCP 1 brown adipose tissue
- UCP 2 and UCP 3 are present in muscle and adipose tissue, and play a role in controlling homeostasis of body energy.
- fat metabolism and sugar metabolism are different compared to the case where the body's metabolic state is not obese, which is due to insulin resistance (insulin resistance) does not appear to play properly. Persistent insulin resistance eventually leads to diabetes, and diabetes due to obesity has been reported in considerable patients.
- Reductil and Xenical which are currently developed anti-obesity medicines, have various side effects such as thirst, dizziness or abdominal bloating, and fatty stool. Research to develop functional food is being actively conducted.
- the green tea composition is 10-2001-22510
- the extract of nectar plants is 10-2003-87280
- the red ginseng extract is 10-2006-115006
- the haejuku branch extract is 10-2007- No. 56192
- yeast extracts 10-2006-38254 vine bark extracts 10-2007-82438
- deficiency extracts 10-2006-91698.
- Diabetes is divided into type 1 and type 2, and type 2 diabetes, which occurs mainly in adults, is caused by lowered insulin secretion and insulin resistance, decreased insulin receptor, insulin receptor substrate-1 (IRS-1, insulin receptor).
- IRS-1 insulin receptor substrate-1
- Cellular deficiency of substrate-1) is known to be caused by various causes such as lack of tyrosine kinase activity. In particular, it is accompanied by various metabolic abnormalities, and is one of chronic diseases with complications such as diabetic retina, renal failure, and diabetic group.
- TZD-based drugs such as troglitazone, pioglitasol and roggigtatazone are known to have fewer side effects than other diabetes treatments, but are still known to cause side effects such as liver toxicity and obesity.
- Antidiabetic effect of Chaga fruiting body extract was 10-2005-36879
- antidiabetic effect of Alder extract was 10-2002-48813
- antidiabetic effect of horseshoe mushroom extract was 10-2003-69748
- mulberry leaf extract The antidiabetic effect of is known from 10-2004-82926, respectively.
- CPT-1 carnitine palmitoyltransferase-1
- ACC is phosphorylated and inactivated by the 5'AMP-activated protein kinase (AMPK), which plays a mechanical role in detecting changes in cellular energy sources.
- AMPK 5'AMP-activated protein kinase
- Exercise increases the activity of AMPK, which phosphorylates ACC, inhibits activity and decreases the concentration of malonyl-CoA.
- malonyl-COA an inhibitor of CPT-1, induces CPT-1 activity and increases the influx of fatty acids acylated into mitochondria.
- Korean Patent Application No. 10-2005-709019 is known as a muscle increasing agent, and a food composition for enhancing exercise performance is disclosed in 10-2003-38486.
- sports science ginseng products are known from 10-1997-12503, and dietary compositions for improving exercise sustainability are known from 10-2007-104898.
- the medicinal plant Piper retrofractam of the present invention is a pepper family (piperaceae family) plants, as a plant native to Southeast Asia, the fruit portion is used in the present invention.
- Retrofractam includes retrofractamide A, retrofractamide B, and retrofractamide C, piperine, and piperine. It contains guineensine, methyl piperate, pelliorine, and piperlongumininie, and it contains antioxidant, antibacterial, insecticidal effects, bioavailability of drugs, and vasodilation. It has been reported to exhibit an exothermic effect.
- the object of the present invention is to obtain an extract from the fruit of Piper retrofractam and to administer the extract to obese and diabetic rats to perform anti-obesity and anti-diabetic effect and muscle mass and exercise performance experiments and to evaluate the results Achieved through the steps.
- composition containing Pfeiffer retrofractam extract according to the present invention can prevent and treat obesity by reducing body weight and body fat, and lowering blood sugar and blood insulin levels to prevent diabetes and at the same time have an excellent effect on increasing muscle mass and improving athletic performance. have.
- Figure 1 showed the mouse weight loss effect according to the treatment of the piper retro fructam extract according to the present invention. ** on the graph indicates that * p ⁇ 0.05, ** p ⁇ 0.01 is significant through Tukey's Multiple Comparison Test, a post test of one-way ANOVA.
- Figure 2 shows the body fat reduction of the mouse according to the treatment of the piper retro fructam extract according to the present invention.
- the ** on the bar graph indicates that * p ⁇ 0.05 and ** p ⁇ 0.01 are significant through Tukey's Multiple Comparison Test, a post hoc test of one-way ANOVA.
- Figure 3 shows whether the activity of the UCP3 protein by using a Western blot in mouse fat cells (3T3-L1) according to the treatment of Pfeiffer retrofractam extract according to the present invention.
- Figure 4 shows that the fasting blood glucose of the mouse according to whether the treatment of the piper retro fructam extract according to the present invention is reduced.
- the ** on the bar graph indicates that * p ⁇ 0.05 and ** p ⁇ 0.01 are significant through Tukey's Multiple Comparison Test, a post hoc test of one-way ANOVA.
- Figure 5 shows that the fasting insulin concentration of the mouse according to whether or not the treatment of the piper retro fructam extract according to the present invention.
- the ** on the bar graph indicates that * p ⁇ 0.05 and ** p ⁇ 0.01 are significant through Tukey's Multiple Comparison Test, a post hoc test of one-way ANOVA.
- Figure 6 shows that HOMA-IR is reduced in the mouse depending on whether or not the treatment of the Pfeiffer retro-fructam extract according to the present invention.
- Figure 7 shows whether the activity of the IRS-1 protein using Western blot in the liver of the mouse according to the treatment of the Pfeiffer retro-fructam extract according to the present invention.
- Figure 8 shows the muscle through the PET / CT scan of the mouse femoral muscles according to the treatment of the Pfeiffer retro-fractam extract according to the present invention.
- Figure 9 shows the volume of the mouse thigh muscle according to the treatment of the Pfeiffer retrofractam extract according to the present invention. Marking ** on the bar graph indicates that it is significant at ** p ⁇ 0.01 through Tukey's Multiple Comparison Test, a post hoc test of one-way ANOVA.
- Figure 10 shows that the content of the muscle is reduced by the use of triglycerides (IMTG) in the mouse muscle as an energy source depending on whether the Pfeiffer retrofractam extract according to the present invention.
- IMTG triglycerides
- Figure 11 shows the effect of improving the exercise power using the treadmill in the mouse according to the treatment of the piper retro fructam extract according to the present invention.
- Marking * on the bar graph indicates that * p ⁇ 0.05 is significant through Tukey's Multiple Comparison Test, a post hoc test of one-way ANOVA.
- Figure 12 shows whether the activity of pAMPK, pACC, CPT-1 protein using Western blot in the mouse muscles according to the treatment of Pfeiffer retrofractam extract according to the present invention.
- composition comprising the Pfeiffer retrofractum extract according to the present invention can prevent and treat obesity by reducing body weight and body fat, prevent and treat diabetes by lowering blood sugar and blood insulin levels, By regulating genes that are easy to use (AMPK activity, ACC inhibition and activity of CPT-1), muscle mass can be increased, and exercise ability can be improved.
- AMPK activity, ACC inhibition and activity of CPT-1 genes that are easy to use
- the Pfeiffer retrofractum fruit extract may be obtained as an organic solvent extract or as a supercritical extract using carbon dioxide or carbon dioxide and an organic solvent together.
- the dried Pfeiffer Retrofractum fruit powder is added to the extracting apparatus with 4 to 10 times the extraction solvent and left to stand for at least 12 hours or supercritical extraction, and the extract is concentrated and dried with a concentrator.
- the extraction solvent may be purified water, methanol, ethanol, propanol, isopropanol, isopropanol, butanol, acetone, ether, benzene. ), Chloroform, ethyl acetate, ethyl acetate, methylenechloride, hexane, cyclohexane, petroleum ether, or mixtures thereof, and the like, and are preferable. Ethanol may be used.
- a solvent suitable for extracting the Pfeiffer retrofractum fruit component as an active ingredient may be used without particular limitation.
- the present invention also provides an anti-obesity and anti-diabetic functional health food and pharmaceutical composition using the composition.
- the health food and pharmaceutical composition comprises the Pfeiffer retrofractum fruit extract according to the present invention, by the UCP activation mechanism of human body fat cells, it is possible to prevent and treat obesity by reducing weight and body fat, blood sugar and blood insulin concentration By lowering insulin resistance can be improved to prevent and treat diabetes.
- AMPK activity, ACC inhibition, and CPT-1 activity increase the fat of aerobic exercise into the mitochondria, which increases muscle mass and improves exercise ability without exercise. Can be effective.
- powders, granules, tablets, pills, tablets of sugars, capsules, solutions, gels according to methods known in the art together with a carrier for oral administration, It can be formulated in the form of syrups, suspensions, wafers and the like.
- suitable carriers include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch cellulose, methyl including starch, wheat starch, rice starch and potato starch and the like.
- Fillers such as cellulose gelatin, polyvinylpyrrolidone, and the like, including cellulose, sodium carboxymethylcellulose, hydroxy propylmethine-cellulose, and the like.
- crosslinked polyvinyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant.
- the pharmaceutical composition may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, and a preservative.
- the high fat diet used in the anti-obesity and anti-diabetic experiments was 40% fat calorie and the Pfeiffer Retroproctum extract was included at 100 mg / kg mouse weight (EXT 100).
- EXT 100 100 mg / kg mouse weight
- Five-week-old male C57BL / 6J mice were randomly placed in the high fat control group (HFD group) and the extract administration group (EXT group) according to the intake dose, and then adapted to the experimental animal room environment for one week. After seven weeks of high fat diet, eight weeks of vehicle or vehicle-dispersed extracts were forced.
- the high fat diet used in the exercise exercise was 40% fat calorie, and Pfeiffer Retroproctum extract was included at 100 mg (PRE100) or 300 mg (PRE300) per kg body weight of the mouse.
- Pfeiffer Retroproctum extract was included at 100 mg (PRE100) or 300 mg (PRE300) per kg body weight of the mouse.
- Five-week-old male C57BL / 6J mice were randomly placed in the high fat control group (HFD group) and the extract administration group 2 (PRE100 and PRE300 group) according to the intake dose, and then adapted to the experimental animal room environment for 1 week. Animals in all groups were fed a High Fat Diet for seven weeks and then forced to use a vehicle or vehicle-dispersed extract for eight weeks.
- HOMA-IR values were calculated from the blood glucose and insulin measurements shown above. The calculation is as follows.
- HOMA-IR FBG (mg.dL) x FI (ng / ml) x 0.0717225161669606
- the piper retroproctum extract ingestion group is significantly reduced in the EXT100 group ingesting the piper retroproctum extract as a test substance compared to the control (HFD) as shown in Figure 6 it can be seen that the insulin resistance is improved.
- the final muscle volume was measured using micro PET / CT (positron emission tomography / Computed tomography, INVEON, Siemens, USA), as shown in FIGS. 8 and 9. Compared to the control group (HFD), 200% was significantly increased in the PRE100 and PRE300 groups fed the Pfeiffer retrofractum extract.
- Piper retrofractum extract was ingested for 8 weeks, sacrificed, muscle extracted, and then stained with Hematoxylin and eosin (H & E) to observe fat content.
- H & E Hematoxylin and eosin
- the exercise power was evaluated using a trade mill. Measured at a speed of 11 m per minute, as a result, as shown in Figure 4, the high-fat diet was significantly increased in the PRE100 group and PRE300 group ingested the extract as compared to the control (HFD) [FIG. 11].
- the present invention has an effect of providing an anti-obesity functional composition derived from retrofractum fruit extract, and in particular, has a function of reducing body weight and body fat, which is characterized by a heat generation mechanism by UCP activity of adipocytes.
- Anti-diabetic functional composition for improving insulin resistance characterized in that the composition, blood sugar, hypoglycemic action before insulin, in particular, has an excellent effect of providing an anti-diabetic functional food and pharmaceutical composition for improving insulin resistance, characterized by an IRS-1 activation mechanism.
- it is a very useful invention in health and medicine because it has an excellent effect of providing functional foods and pharmaceutical compositions for muscle mass gain, exercise improvement and fatigue recovery characterized by ACC inhibition and CPT-1 activity due to AMPK activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (18)
- 약용식물 파이퍼 레트로프락텀(Piper retrofractum Vahl.) 열매의 추출물을 유효성분으로 함유하고 체중 및 체지방 감소기전을 특징으로 하는 항비만 기능성 식품 조성물.
- 제 1항에 있어서,상기 파이퍼 레트로프락텀 추출물은 열매의 분말을 유기 용매 추출하거나 초임계 추출하는 것을 특징으로 하는 항비만 기능성 식품 조성물.
- 파이퍼 레트로프락텀 열매의 추출물을 유효성분으로 함유하고 지방세포의 UCP 활성에 의한 열발생기전을 특징으로 하는 항비만 약제학적 조성물.
- 제 3항에 있어서, 상기 조성물이 체중 및 체지방 감소 기전을 특징으로 하는 항비만 건강 보조 의약 부외품.
- 제 3항에 있어서, 상기 파이퍼 레트로프락텀 열매의 추출물은 조성물 총 중량에 대하여 0.001 내지 80 중량 %의 함량으로 포함되어 있는 것을 특징으로 하는 체중 및 체지방 감소기전을 특징으로 하는 항비만 약제학적 조성물.
- 제 1항 기재의 조성물이 분말, 과립, 정제, 캅셀, 시럽제 또는 음료 중 어느 하나의 형태인 것을 특징으로 하고 지방세포의 UCP 활성으로 인한 발열작용에 의한 체중 및 체지방 감소 기전을 특징으로 하는 항비만 기능성 식품 조성물.
- 약용식물 파이퍼 레트로프락텀(Piper retrofractum Vahl.) 열매의 추출물을 유효성분으로 함유하고 혈당, 혈중 인슐린 저하기전을 특징으로 하는 인슐린 저항성 개선용 항당뇨 기능성 식품 조성물.
- 제 7항에 있어서, 파이퍼 레트로프락텀 추출물은 열매의 분말을 유기 용매 추출하거나 초임계 추출하는 것을 특징으로 하는 항당뇨 기능성 식품 조성물.
- 파이퍼 레트로프락텀 열매의 추출물을 유효성분으로 함유하고 IRS-1 활성기전을 특징으로 하는 인슐린 저항성 개선용 항당뇨 약제학적 조성물.
- 제 9항에 있어서, 상기 조성물이 혈당, 혈중 인슐린 저하기전을 특징으로 하는 인슐린 저항성 개선용 항당뇨 건강 보조 의약 부외품.
- 제 9항에 있어서, 상기 파이퍼 레트로프락텀 열매의 추출물은 조성물 총 중량에 대하여 0.001 내지 80 중량 %의 함량으로 포함되어 있는 것을 특징으로 하는 혈당, 혈중 인슐린 저하기전을 특징으로 하는 인슐린 저항성 개선용 항당뇨 약제학적 조성물.
- 제 7항 기재의 조성물이 분말, 과립, 정제, 캅셀, 시럽제 또는 음료 중 어느 하나의 형태인 것을 특징으로 하는 혈당, 혈중 인슐린 저하기전을 특징으로 하는 인슐린 저항성 개선용 항당뇨 기능성 식품 조성물.
- 약용식물 파이퍼 레트로프락텀(Piper retrofractum Vahl.) 열매의 추출물을 유효성분으로 함유하고 근육량 증대, 운동능력향상 및 피로회복 기전을 특징으로 하는 건강 기능성 식품 조성물.
- 제 13항에 있어서,파이퍼 레트로프락텀 추출물은 열매의 분말을 유기 용매 추출하거나 초임계 추출하는 것을 특징으로 하는 건강 기능성 식품 조성물.
- 파이퍼 레트로프락텀 열매의 추출물을 유효성분으로 함유하고 AMPK 활성기전을 특징으로 하는 약제학적 조성물.
- 제 15항에 있어서,상기 조성물은 근육량 증대, 운동력 향상 및 피로회복을 특징으로 하는 약제학적 조성물.
- 제 15항에 있어서,상기 파이퍼 레트로프락텀 열매의 추출물은 조성물 총 중량에 대하여 0.001 내지 80 중량 %의 함량으로 포함되어 있는 것을 특징으로 하는 근육량 증대, 운동력 향상 및 피로회복 기전을 특징으로 하는 약제학적 조성물.
- 제 13항 기재의 조성물이 분말, 과립, 정제, 캅셀, 시럽제 또는 음료 중 어느 하나의 형태인 것을 특징으로 하는 근육량 증대, 운동력 향상 및 피로회복 기전을 특징으로 하는 건강 기능성 식품 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/122,752 US20140186473A1 (en) | 2011-05-31 | 2012-05-31 | Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients |
JP2014513442A JP2014516983A (ja) | 2011-05-31 | 2012-05-31 | 肥満や糖尿病を治療するため及び筋肉量を増加して運動能力を向上させるための組成物であって、有効成分としてヒハツモドキ果実(piperretrofractumvahl.fruits)の抽出成分を含む組成物 |
CN201280027034.9A CN103717229A (zh) | 2011-05-31 | 2012-05-31 | 以假荜拔果实提取物为有效成份的抗肥胖、抗糖尿病、肌肉量增加及运动能力提升用组合物 |
US15/433,552 US20170209511A1 (en) | 2011-05-31 | 2017-02-15 | Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0052190 | 2011-05-31 | ||
KR1020110052191A KR101476761B1 (ko) | 2011-05-31 | 2011-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만용 조성물 |
KR1020110052190A KR20120133515A (ko) | 2011-05-31 | 2011-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항당뇨용 조성물 |
KR10-2011-0052191 | 2011-05-31 | ||
KR1020110053484A KR101309849B1 (ko) | 2011-06-02 | 2011-06-02 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 근육량 증대 및 운동력 향상용 조성물 |
KR10-2011-0053484 | 2011-06-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/122,752 A-371-Of-International US20140186473A1 (en) | 2011-05-31 | 2012-05-31 | Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients |
US15/433,552 Continuation US20170209511A1 (en) | 2011-05-31 | 2017-02-15 | Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2012165888A2 WO2012165888A2 (ko) | 2012-12-06 |
WO2012165888A9 true WO2012165888A9 (ko) | 2013-03-28 |
WO2012165888A3 WO2012165888A3 (ko) | 2013-05-16 |
Family
ID=47260097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/004325 WO2012165888A2 (ko) | 2011-05-31 | 2012-05-31 | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만, 항당뇨 및 근육량 증대및 운동력 향상용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20140186473A1 (ko) |
JP (2) | JP2014516983A (ko) |
CN (2) | CN104547059B (ko) |
HK (1) | HK1204566A1 (ko) |
WO (1) | WO2012165888A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109381462A (zh) * | 2018-12-13 | 2019-02-26 | 中国科学院新疆理化技术研究所 | 一种荜茇酰胺类生物碱的降糖用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3645608B2 (ja) * | 1995-03-10 | 2005-05-11 | 花王株式会社 | 脂肪分解促進剤 |
JP2000136141A (ja) * | 1998-10-30 | 2000-05-16 | Sumitomo Forestry Co Ltd | 抗菌剤 |
JP2002138045A (ja) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | 前駆脂肪細胞分化誘導剤 |
JP2004002267A (ja) * | 2002-03-28 | 2004-01-08 | Kobayashi Pharmaceut Co Ltd | コラゲナーゼ阻害剤及びその利用 |
CA2505140A1 (en) * | 2002-10-29 | 2004-05-21 | Council Of Scientific And Industrial Research | New alpha-glucosidase inhibitors from a natural source |
CN100356940C (zh) * | 2004-12-01 | 2007-12-26 | 蒋毅 | 制备大叶蒟提取物的方法、提取物及其应用 |
JP2007131568A (ja) * | 2005-11-09 | 2007-05-31 | Nippon Seiyaku Kogyo Kk | 免疫賦活剤及びこれを含有する免疫賦活性飲食物 |
JP5158307B2 (ja) * | 2006-09-15 | 2013-03-06 | ライオン株式会社 | 脂肪減少促進剤及び代謝異常症候群改善薬 |
KR100805745B1 (ko) * | 2006-10-27 | 2008-02-21 | 한국생명공학연구원 | 비만 또는 제2형 당뇨병의 예방 또는 치료용 조성물 |
JP2011073973A (ja) * | 2009-09-29 | 2011-04-14 | Shiseido Co Ltd | 更年期のための疲労改善組成物 |
-
2012
- 2012-05-31 US US14/122,752 patent/US20140186473A1/en not_active Abandoned
- 2012-05-31 JP JP2014513442A patent/JP2014516983A/ja active Pending
- 2012-05-31 CN CN201410842636.0A patent/CN104547059B/zh active Active
- 2012-05-31 CN CN201280027034.9A patent/CN103717229A/zh active Pending
- 2012-05-31 WO PCT/KR2012/004325 patent/WO2012165888A2/ko active Application Filing
-
2015
- 2015-05-29 HK HK15105136.7A patent/HK1204566A1/xx unknown
-
2016
- 2016-03-09 JP JP2016045156A patent/JP6255432B2/ja active Active
-
2017
- 2017-02-15 US US15/433,552 patent/US20170209511A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2012165888A3 (ko) | 2013-05-16 |
JP2016165282A (ja) | 2016-09-15 |
HK1204566A1 (en) | 2015-11-27 |
CN104547059A (zh) | 2015-04-29 |
US20140186473A1 (en) | 2014-07-03 |
US20170209511A1 (en) | 2017-07-27 |
JP6255432B2 (ja) | 2017-12-27 |
WO2012165888A2 (ko) | 2012-12-06 |
CN103717229A (zh) | 2014-04-09 |
JP2014516983A (ja) | 2014-07-17 |
CN104547059B (zh) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008067639A1 (en) | Composition for promoting weight loss comprising yohimbine, evodia rutaecarpia extract and l-carnitine | |
EP2052729B1 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia | |
WO2017191856A1 (ko) | 지페노사이드 75의 항당뇨 효과 | |
WO2016085068A1 (ko) | 복합추출물을 함유하는 운동수행능력 증강 및 체력증진용 조성물 | |
Song et al. | Effects of traditional Chinese herbal feed supplement on growth performance, immunity, antioxidant levels, and intestinal health in chickens: a study on Ningdu yellow chickens | |
KR20020092082A (ko) | 자양강장제 조성물 | |
CN111686199A (zh) | 一种抗疲劳的枸杞组合物 | |
EP1690519A1 (en) | Alpha-glucosidase activity inhibitor | |
WO2012165888A9 (ko) | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만, 항당뇨 및 근육량 증대및 운동력 향상용 조성물 | |
TW200816983A (en) | Anthracenedione compounds | |
CN102731597A (zh) | 黄蜀葵花提取物及其化学成分的新用途 | |
JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
CN106349318B (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
JP2015193547A (ja) | 運動様作用を有するレスベラトロール加熱処理組成物 | |
WO2020122373A1 (ko) | 자감초 추출물을 유효성분으로 포함하는 남성갱년기 증후군의 예방, 개선 또는 치료용 조성물 | |
TW202200129A (zh) | 菸鹼醯胺腺嘌呤二核苷酸(nad)濃度上昇劑 | |
Ma et al. | Influence of Ligustrum lucidum and Schisandra chinensis fruits on antioxidative metabolism and immunological parameters of layer chicks | |
KR100824704B1 (ko) | 지실 추출물을 유효성분으로 함유하는 비만 치료 및 예방용조성물 | |
KR101476761B1 (ko) | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 항비만용 조성물 | |
CN106176959A (zh) | 改善第二型糖尿病的芭乐果实及海藻糖饮食组成物与用途 | |
KR20050079913A (ko) | 헛개나무 추출물을 포함하는 비만 예방 및 치료를 위한조성물 | |
KR101309849B1 (ko) | 파이퍼 레트로프락텀 열매추출물을 유효성분으로 포함하는 근육량 증대 및 운동력 향상용 조성물 | |
KR101645589B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 알코올성 숙취 예방, 숙취 해소, 간장 보호 또는 피로 회복용 조성물 | |
Beynen | Quercetin for dogs | |
CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12793252 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014513442 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14122752 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12793252 Country of ref document: EP Kind code of ref document: A2 |